Literature DB >> 29378694

Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma.

Benjamin Solomon1,2,3, Richard J Young4,3, Mathias Bressel5, Damien Urban4,2, Shona Hendry6, Alesha Thai2, Christopher Angel3,6, Afaf Haddad7,8, Marcin Kowanetz9, Tsien Fua10, June Corry11, Stephen Fox3,6, Danny Rischin2,3.   

Abstract

Human papilloma virus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) represents a distinct subgroup of head and neck cancers associated with clinical outcomes that are not accurately categorized by existing tumor-node-metastasis-based staging methods. Given the significant impact of immune parameters, such as tumor-infiltrating lymphocytes (TIL) in many cancers, we sought to determine if immunophenotyping tumors can improve categorization of HPV+ OPSCCs for prognostic purposes. In a cohort of 190 patients with HPV+ OPSCC, we quantified and determined the localization of CD8+ TILs, as well as PD-L1-expressing tumor cells (TC) and immune cells (IC). The prognostic significance of these parameters on overall survival (OS) was evaluated, and their contribution to existing prognostic models was determined. High CD8+ TIL abundance (≥30% on stromal or intratumoral ICs) was seen in 61.3% patients and was associated with improved OS [HR, 0.4; 95% confidence interval (CI), 0.2-0.9; P = 0.017]. Although the expression of PD-L1 on TC was not prognostic, high expression of PD-L1 on ≥5% of intratumoral ICs was found in 38.5% patients and was significantly associated with improved OS (HR, 0.37; 95% CI, 0.15-0.93; P = 0. 023). Both high intratumoral IC PD-L1 expression and abundant CD8+ TILs in HPV+ OPSCCs identify subgroups of patients with excellent outcomes and provide additional prognostic information beyond existing staging systems. Cancer Immunol Res; 6(3); 295-304. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29378694     DOI: 10.1158/2326-6066.CIR-17-0299

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  32 in total

1.  A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Authors:  Richard D Kim; Vincent Chung; Olatunji B Alese; Bassell F El-Rayes; Daneng Li; Taymeyah E Al-Toubah; Michael J Schell; Jun-Min Zhou; Amit Mahipal; Baek Hui Kim; Dae Won Kim
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas.

Authors:  Anne-Kathrin Hess; Korinna Jöhrens; Andre Zakarneh; Panagiotis Balermpas; Jens Von Der Grün; Claus Rödel; Wilko Weichert; Michael Hummel; Ulrich Keilholz; Volker Budach; Ingeborg Tinhofer
Journal:  Oncoimmunology       Date:  2019-05-25       Impact factor: 8.110

3.  Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.

Authors:  Yi Luo; Yi-Chen Yang; Cen-Kai Shen; Ben Ma; Wei-Bo Xu; Qi-Feng Wang; Yan Zhang; Tian Liao; Wen-Jun Wei; Yu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

4.  Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.

Authors:  Jacqueline E Mann; Joshua D Smith; Andrew C Birkeland; Emily Bellile; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Jeffery S Moyer; Gregory T Wolf; Carol R Bradford; Mark E Prince; Thomas E Carey; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Cancer Immunol Immunother       Date:  2018-10-25       Impact factor: 6.968

5.  Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.

Authors:  Claire Smalley Rumfield; Samuel T Pellom; Jeffrey Schlom; Caroline Jochems; Y Maurice Morillon Ii
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

Review 6.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.

Authors:  Ming Yi; Dechao Jiao; Hanxiao Xu; Qian Liu; Weiheng Zhao; Xinwei Han; Kongming Wu
Journal:  Mol Cancer       Date:  2018-08-23       Impact factor: 27.401

Review 7.  Immunotherapy in extensive small cell lung cancer.

Authors:  Vaibhav Verma; Geeti Sharma; Abhijai Singh
Journal:  Exp Hematol Oncol       Date:  2019-02-04

Review 8.  Activation of viral defense signaling in cancer.

Authors:  Maria Gonzalez-Cao; Niki Karachaliou; Mariacarmela Santarpia; Santiago Viteri; Andreas Meyerhans; Rafael Rosell
Journal:  Ther Adv Med Oncol       Date:  2018-08-29       Impact factor: 8.168

9.  Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Authors:  Steven F Gameiro; Farhad Ghasemi; John W Barrett; James Koropatnick; Anthony C Nichols; Joe S Mymryk; Saman Maleki Vareki
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

10.  Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis.

Authors:  Yi-Qun Jia; Bo Yang; Li-Ling Wen; Wen-Xin Mu; Zhi Wang; Bin Cheng
Journal:  Aging (Albany NY)       Date:  2019-01-22       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.